Acute Myeloid LeukemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

3556 records returned

The Interferon Consensus Sequence Binding Protein (ICSBP/IRF8) Activates Transcription of the FANCF Gene during Myeloid Differentiation [Transcription, Chromatin, and Epigenetics]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The interferon consensus sequence binding protein (ICSBP) is an interferon regulatory transcription factor with leukemia-suppressor activity. ICSBP regulates genes that are involved in phagocyte function, proliferation, and apoptosis. In murine models ICSBP deficiency results in a myeloproliferative disorder (MPD) with increased mature neutrophils. Over time this MPD progresses to acute myeloid leukemia (AML), suggesting that ICSBP deficiency is adequate for MPD, but additional genetic lesions are required for AML. The hypothesis of these studies is that dysregulation of key target genes predisposes to disease progression ...
Source: Journal of Biological Chemistry - November 20, 2009 Category: Chemistry Authors: Saberwal, G., Horvath, E., Hu, L., Zhu, C., Hjort, E., Eklund, E. A. Tags: Transcription, Chromatin, and Epigenetics Source Type: journals

AML1 amplification and 17q25 deletion in a case of childhood acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of childhood acute lymphoblastic leukemia (ALL) with both acute myeloid leukemia 1 (AML1) amplification and 17q25 deletion. AML1 gene is located on 21q22 and encodes a transcription factor. AML1 amplification is a common finding in childhood ALL, and itis observed as an increase in gene copy number by the FISH analysis. The mechanism of AML1 amplification is not associated with AML1 gene mutations. The 17q25 is a gene-rich chromosomal location and distinct abnormalities of this region have been observed in previous cases of different kinds of leukemia. Deletion of the 17q25 region has been reported in two ...
Source: Journal of Clinical Laboratory Analysis - November 19, 2009 Category: Laboratory Medicine Authors: Tuna Gulten, Tahsin Yakut, Mutlu Karkucak, Birol Baytan, Adalet Meral Gune[scedil] Tags: Original Articles Source Type: journals

Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion AML in the elderly represents a distinct biologic entity characterized by unique patterns of deregulated signaling pathway variations that contributes to poor survival and anthracycline resistance. These insights should enable development and adjustments of clinically meaningful treatment strategies in the older patient population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Rao, Valk, Metzeler, Acharya, Tuchman, Stevenson, Rizzieri, Delwel, Buske, Bohlander, Potti, Lowenberg Tags: Epidemiology, Translational Oncology, Hematologic, Other, Gene Expression and Profiling Hematologic Malignancies Source Type: journals

Chronic myelogenous leukemia and benzene exposure: a systematic review and meta-analysis of the case-control literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Benzene exposure is well demonstrated as a cause of acute myelogenous leukemia, but not of chronic myelogenous leukemia. Previous literature reviews based on case series and cohort studies have not shown an association. We have now conducted a literature search for case-control studies that examine the association between benzene exposure and chronic myelogenous leukemia. Six case-control studies have been found. These derive from occupational groups, cancer registries, and a clinical laboratory. Their exposure ascertainments are all based on job histories, job-exposure matricies, or industrial hygiene data. The odds r...
Source: Chemico-Biological Interactions - November 18, 2009 Category: Molecular Biology Authors: Lamm SH, Engel A, Joshi KP, Byrd DM, Chen R Tags: Chem Biol Interact Source Type: journals

Erratum to: Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory ErratumDOI 10.1007/s00277-009-0860-1Authors Antonio R. Lucena-Araujo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilDanielle L. Souza, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilFabio Morato de Oliveira, University of São Paulo Hematology Division, Department of Internal...
Source: Annals of Hematology - November 18, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Health Organization classification as well as six prognostic scoring systems in these patients. The median follow-up time was 25.1 months (5.5–53.2). Of the 435 patients, 186 (42.8%) had died and 40 (9.2%) had progressed to acute myeloid leukemia. Multivariate analysis identified older age, higher percent of marrow blasts, and poor-risk IPSS cytogenetics as characteristics associated with worse survival and higher risk of leukemia transf...
Source: Annals of Hematology - November 18, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S. (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - November 18, 2009 Category: Respiratory Medicine Source Type: consumer

Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Imahashi N, Inamoto Y, Seto A, Watanabe K, Nishiwaki S, Yanagisawa M, Shinba M, Yasuda T, Kuwatsuka Y, Atsuta Y, Kodera Y, Miyamura K. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Clin Transplant 2009 DOI: 10.1111/j.1399-0012.2009.01158.x© 2009 John Wiley & Sons A/S.Abstract: Corticosteroids are often used following allogeneic hematopoietic stem cell transplantation (HSCT) to control complications such as graft-versus-host disease (GVHD). However, there is some concern that corticosteroids may suppress the graft-versus-leukemia effect and i...
Source: Clinical Transplantation - November 18, 2009 Category: Transplant Surgery Authors: Nobuhiko Imahashi, Yoshihiro Inamoto, Aika Seto, Keisuke Watanabe, Satoshi Nishiwaki, Mayumi Yanagisawa, Makoto Shinba, Takahiko Yasuda, Yachiyo Kuwatsuka, Yoshiko Atsuta, Yoshihisa Kodera, Koichi Miyamura Source Type: journals

Molecular diagnostics in acute leukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinical Chemistry and Laboratory Medicine 47 (11): 1333-1341 Abstract Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) both represent highly heterogeneous entities on the basis of diverse cyto- and molecular genetic alterations with considerable influence on prognosis and therapeutic decisions. In recent years, insights into the complex network of molecular markers underlying this diversity have shown marked progress due to the detection of novel mutations, such as nucleophosmin gene (NPM1) in AML, and due to the description of cooperation pathways in leukemogenesis. Also, targeted therapeutic strategie...
Source: Clinical Chemistry and Laboratory Medicine - November 16, 2009 Category: Laboratory Medicine Source Type: journals

Diagnosis and treatment of maternal acute myeloid leukemia during pregnancy imitating HELLP syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Perinatal Medicine 37 (6): 713-714 No abstract available (Source: Journal of Perinatal Medicine)
Source: Journal of Perinatal Medicine - November 13, 2009 Category: Perinatology & Neonatology Source Type: journals

Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Khat activated a distinct cell death pathway in sensitive leukemic cells as compared to camptothecin, involving mitochondrial damage and morphological features of autophagy. This suggests that khat should be further explored in the search for novel experimental therapeutics. (Source: Molecular Cancer)
Source: Molecular Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Therese BredholtElizabeth DimbaHanne HaglandLine WergelandJorn SkavlandKjell FossanKarl TronstadAnne JohannessenOlav VintermyrBjorn Gjertsen Source Type: journals

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Blood)
Source: Blood - November 12, 2009 Category: Hematology Authors: Micol, J. B., Boissel, N., Renneville, A., Castaigne, S., Gardin, C., Preudhomme, C., Dombret, H. Tags: CORRESPONDENCE Source Type: journals

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genomic instability in solid tumors participates in the oncogenetic process and is associated with the activation of the DNA damage response pathway. Here, we report the activation of the constitutive DNA damage and checkpoint pathway associated with complex karyotypes in samples from patients with acute myeloid leukemia (AML). We show that antagonizing CHK1 kinase with a small inhibitory compound or by RNA interference strongly reduces the clonogenic properties of high–DNA damage level AML samples, particularly those with complex karyotypes. Moreover, we observe a beneficial effect of CHK1 inhibition in high–D...
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Cavelier, C., Didier, C., Prade, N., Mansat-De Mas, V., Manenti, S., Recher, C., Demur, C., Ducommun, B. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In cancer genomes, changes observed during tumor progression can be difficult to separate from nonspecific accumulation of cytogenetic changes due to cancer-associated genetic instability. We studied genetic changes occurring over time in cancers presenting with a relatively simple karyotype, namely two related core-binding factor (CBF) acute myeloid leukemias (AMLs), to assess how specific chromosomal changes are selected based on tumor subtype and acquired somatic mutations. Expression profiles for DNA replication/repair genes and the mutation status of KRAS, NRAS, FLT3, and KIT were compared with the karyotypic changes ...
Source: Genes, Chromosomes and Cancer - November 12, 2009 Category: Cancer & Oncology Authors: Dan Jones, Hui Yao, Angela Romans, Caroline Dando, Sherry Pierce, Gautam Borthakur, Amy Hamilton, Carlos Bueso-Ramos, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian Source Type: journals

Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 56-year-old woman with acute myelomonocytic leukemia underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-SCT) from a matched unrelated donor in her first complete remission (CR). Veno-occlusive disease (VOD) prophylaxis consisted of low-dose heparin and ursodeoxycholic acid. Graft-versus-host disease (GVHD) prophylaxis comprised tacrolimus and short-term methotrexate. On day 14, VOD developed, but gradually resolved with supportive therapy. On day 58, she showed grade II acute GVHD, but this resolved spontaneously. On day 140, she developed hematological relapse with 40.2% marrow infiltra...
Source: International Journal of Hematology - November 11, 2009 Category: Hematology Authors: Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H Tags: Int J Hematol Source Type: journals

Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0855-yAuthors Sumimasa Nagai, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanYasuhito Nannya, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanTsuyoshi Takahashi, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanMineo Kurokawa, University of Tokyo Department of Hematology and Oncology, Graduate Schoo...
Source: Annals of Hematology - November 10, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Voreloxin Granted Orphan Drug Status for Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration has granted orphan drug designation for voreloxin in the treatment of acute myeloid leukemia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2009 Category: Consumer Health News Tags: Pharmacist Source Type: news

Targeting of AML-leukemic stem cells with monoclonal antibodiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Future Oncology , November 2009, Vol. 5, No. 9, Pages 1327-1330. (Source: Future Oncology)
Source: Future Oncology - November 10, 2009 Category: Cancer & Oncology Tags: article Source Type: journals

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 10, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is within 300 days. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 10, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

CLIP down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T cell responses.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions These data emphasize the relevance of CLIP expression on leukemic blasts and the potential of CLIP as a target for immunomodulatory strategies to enhance HLA class II antigen presentation and CD4(+) T cell reactivity in AML. PMID: 19903675 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - November 10, 2009 Category: Hematology Authors: van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA Tags: Haematologica Source Type: journals

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Rapamycin at 2mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti-leukemic effects in these patients. PMID: 19892307 [PubMed - in process] (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - November 8, 2009 Category: Internal Medicine Authors: Boehm A, Mayerhofer M, Herndlhofer S, Knoebl P, Sillaber C, Sperr WR, Jaeger U, Valent P Tags: Eur J Intern Med Source Type: journals

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10 [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Mandelli, Vignetti, Suciu, Stasi, Petti, Meloni, Muus, Marmont, Marie, Labar, Thomas, Di Raimondo, Willemze, Liso, Ferrara, Baila, Fazi, Zittoun, Amadori, de Witte Tags: Clinical Trials, leukemia, Chemotherapy Hematologic Malignancies Source Type: journals

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is requiredEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature. Six new cases of acute myeloid leukaemia were observed by prospectively following two Spanish series of 142 and 88 patients with worsening relapsing multiple sclerosis and secondary-progressive disease treated with mitoxantrone. A literature review shows 32 further cases of acute myeloid leukaemia reported, 65.6% of which are therapy-related acute promyelocytic leu...
Source: Multiple Sclerosis - November 6, 2009 Category: Neurology Authors: Pascual, A. M, Tellez, N., Bosca, I., Mallada, J., Belenguer, A., Abellan, I., Sempere, A. P, Fernandez, P., Magraner, M. J., Coret, F., Sanz, M. A, Montalban, X., Casanova, B. Tags: Articles Source Type: journals

Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Molecular Pharmaceutics, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - November 6, 2009 Category: Drugs & Pharmacology Tags: article Source Type: journals

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 6, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - November 6, 2009 Category: Respiratory Medicine Source Type: consumer

Pharmacogenomics in acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pharmacogenomics , November 2009, Vol. 10, No. 11, Pages 1839-1851. (Source: Future Medicine: Pharmacogenomics)
Source: Future Medicine: Pharmacogenomics - November 5, 2009 Category: Genetics & Stem Cells Tags: article Source Type: journals

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Somatic mutations of Kit have been found in leukemias and gastrointestinal stromal tumors. The proto-oncogene c-Cbl negatively regulates Kit and Flt3 by its E3 ligase activity and acts as a scaffold. We recently identified the first c-Cbl mutation in human disease in an acute myeloid leukemia patient, called Cbl-R420Q. Here we analyzed the role of Cbl mutants on Kit-mediated transformation. Coexpression of Cbl-R420Q or Cbl-70Z with Kit induced cytokine-independent proliferation, survival, and clonogenic growth. Primary murine bone marrow retrovirally transduced with c-Cbl mutants and transplanted into mice led to a general...
Source: Blood - November 5, 2009 Category: Hematology Authors: Bandi, S. R., Brandts, C., Rensinghoff, M., Grundler, R., Tickenbrock, L., Kohler, G., Duyster, J., Berdel, W. E., Muller-Tidow, C., Serve, H., on behalf of the Study Alliance leukemias, Sargin, B. Tags: Myeloid Neoplasia Source Type: journals

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 unitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia. This analysis was performed to identify risk factors associated with leukemia relapse following myeloablative UCB transplantation. Acute leukemia patients (n = 177; 88 with acute lymphoblastic leukemia and 89 with acute myeloid leukemia) were treated at a single center. Patients received a UCB graft composed of either 1 (47%) or 2 (53%) partially human leukocyte antigen (HLA)–matched unit(s). Conditioning was with cyclophosphamide and total body irradiation with or without fludarabine. The incidence of relapse was 26% (95% confiden...
Source: Blood - November 5, 2009 Category: Hematology Authors: Verneris, M. R., Brunstein, C. G., Barker, J., MacMillan, M. L., DeFor, T., McKenna, D. H., Burke, M. J., Blazar, B. R., Miller, J. S., McGlave, P. B., Weisdorf, D. J., Wagner, J. E. Tags: Transplantation, Free Research Articles Source Type: journals

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although the cancer stem cell (CSC) concept implies that CSCs are rare, recent reports suggest that CSCs may be frequent in some cancers. We hypothesized that the proportion of leukemia stem cells would vary as a function of the number of dysregulated pathways. Constitutive expression of MN1 served as a 1-oncogene model, and coexpression of MN1 and a HOX gene served as a 2-oncogene model. Leukemia-initiating cell (LIC) number and in vitro expansion potential of LICs were functionally assessed by limiting dilution analyses. LIC expansion potential was 132-fold increased in the 2- compared with the 1-oncogene model, although...
Source: Blood - November 5, 2009 Category: Hematology Authors: Heuser, M., Sly, L. M., Argiropoulos, B., Kuchenbauer, F., Lai, C., Weng, A., Leung, M., Lin, G., Brookes, C., Fung, S., Valk, P. J., Delwel, R., Lowenberg, B., Krystal, G., Humphries, R. K. Tags: Plenary Papers, Myeloid Neoplasia Source Type: journals

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Laromustine is a sulfonylhdrazine alkylator with significant antileukemia activity. An international, randomized (2:1), double-blind, placebo-controlled study was conducted to compare complete remission (CR) rates and overall survival (OS) in patients with first relapse acute myeloid leukemia (AML) treated with laromustine and high-dose cytarabine (HDAC) versus HDAC/placebo. Patients received 1.5 g/m2 per day cytarabine continuous infusion for 3 days and laromustine 600 mg/m2 (n = 177) or placebo (n = 86) on day 2. Patients in CR received consolidation with laromustine/HDAC or HDAC/placebo as per initial randomization. Aft...
Source: Blood - November 5, 2009 Category: Hematology Authors: Giles, F., Vey, N., DeAngelo, D., Seiter, K., Stock, W., Stuart, R., Boskovic, D., Pigneux, A., Tallman, M., Brandwein, J., Kell, J., Robak, T., Staib, P., Thomas, X., Cahill, A., Albitar, M., O'Brien, S. Tags: Free Research Articles, Myeloid Neoplasia, Clinical Trials and Observations Source Type: journals

Interview: Acute myeloid leukemia patient genome interviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Personalized Medicine , November 2009, Vol. 6, No. 6, Pages 621-622. (Source: Future Medicine: Personalized Medicine)
Source: Future Medicine: Personalized Medicine - November 5, 2009 Category: Genetics & Stem Cells Tags: article Source Type: journals

Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)
Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - November 5, 2009 Category: Cancer & Oncology Source Type: clinical trials

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed.In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m2 per day (8.9 mg/m2 per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplant...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Hiroto Inaba, Clinton F. Stewart, Kristine R. Crews, Shengping Yang, Stanley Pounds, Ching-Hon Pui, Jeffrey E. Rubnitz, Bassem I. Razzouk, Raul C. Ribeiro Source Type: journals

Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Antifungal prophylaxis during first remission induction chemotherapy for acute myelogenous leukaemia requires broad spectrum azoles. In a clinical trial, therapeutic drug monitoring (TDM) of antifungal prophylaxis with voriconazole 200 mg bid was evaluated in a population of six patients. High pressure liquid chromatography was applied. Trough levels were obtained 24 h after the last voriconazole dose. Median time of voriconazole exposure prior to sample acquisition was 16 days (range 9[ndash]21). The mean voriconazole concentration was 486 [mu]g l[minus]1 and ranged from 136 [mu]g l[minus]1 to 1257 [mu]g l[minus]1. Among ...
Source: Mycoses - November 4, 2009 Category: Research Authors: Maria J. G. T. Rüping, Carsten Müller, Jörg J. Vehreschild, Angelika Böhme, Sabine Mousset, Urs Harnischmacher, Peter Frommolt, Gernot Wassmer, Ivonne Drzisga, Michael Hallek, Oliver A. Cornely Source Type: journals